share_log

金斯瑞生物科技：翌日披露報表

GENSCRIPT BIO: Next Day Disclosure Return

香港交易所 ·  Mar 26 12:23
Summary by Futu AI
金斯瑞生物科技股份有限公司於2024年3月26日提交了翌日披露報表，披露其已發行股本出現變動。該公司根據2015年12月7日通過的股份期權計劃，於2024年2月29日至3月25日期間，透過多次行使股份期權及限制性股份獎勵計劃發行新股。股份期權行使價格介乎HKD 3.45至HKD 13.84，而發行價格相對於市值的折讓幅度介乎-5.46%至-99.95%。總共發行的股份數目為123,870股，佔公司於發行前已發行股份的0.0211%。公司確認所有發行均獲董事會批准，並已符合香港聯合交易所有限公司證券上市規則的相關規定。
金斯瑞生物科技股份有限公司於2024年3月26日提交了翌日披露報表，披露其已發行股本出現變動。該公司根據2015年12月7日通過的股份期權計劃，於2024年2月29日至3月25日期間，透過多次行使股份期權及限制性股份獎勵計劃發行新股。股份期權行使價格介乎HKD 3.45至HKD 13.84，而發行價格相對於市值的折讓幅度介乎-5.46%至-99.95%。總共發行的股份數目為123,870股，佔公司於發行前已發行股份的0.0211%。公司確認所有發行均獲董事會批准，並已符合香港聯合交易所有限公司證券上市規則的相關規定。
Kingsway Biotechnology Co., Ltd. filed a Next Day Disclosure Report on March 26, 2024, disclosing the change in its issued share capital. Under the share option plan approved on 7 December 2015, the Company issued new shares from 29 February to 25 March 2024 through multiple exercise of share options and a restricted share bonus scheme. The share option exercise price ranges from HKD 3.45 to HKD 13.84, while the issue price has a discount margin of -5.46% to -99.95% relative to market value. The total number of shares issued was 123,870 shares, representing 0.0211% of the company's shares issued prior to issuance. The Company confirms that all issues have been approved by the Board of Directors and have complied with the relevant provisions of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Kingsway Biotechnology Co., Ltd. filed a Next Day Disclosure Report on March 26, 2024, disclosing the change in its issued share capital. Under the share option plan approved on 7 December 2015, the Company issued new shares from 29 February to 25 March 2024 through multiple exercise of share options and a restricted share bonus scheme. The share option exercise price ranges from HKD 3.45 to HKD 13.84, while the issue price has a discount margin of -5.46% to -99.95% relative to market value. The total number of shares issued was 123,870 shares, representing 0.0211% of the company's shares issued prior to issuance. The Company confirms that all issues have been approved by the Board of Directors and have complied with the relevant provisions of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.